Search

everythinglearnresearchcommunity

for

Search:↓

Anti-TNF-α therapy may increase the risk of developing alopecia areata, especially in those with a history of autoimmune disease.

Alopecia areata is caused by immune attacks on hair follicles, affecting hair growth and quality of life.

More precise, personalized therapies are needed for autoimmune diseases.

NKG2D+CD4+ T cells are higher in alopecia areata patients and may be involved in the disease.

Some people with chronic hair loss may have thyroid autoimmunity.

Alopecia areata is now understood to be driven by genetic and immune factors.

Autoimmune polyglandular syndrome can cause temporary brain issues that may improve on their own.

The study developed a mouse model for Alopecia Areata that responds to treatment, useful for future research.

Bullous pemphigoid, intrahepatic cholangiocarcinoma, and alopecia areata may share immune-related causes.

The study concluded that there is no significant link between thyroid autoimmunity and alopecia areata.

Pertussis toxin may contribute to hair loss in alopecia areata.

The rs231775 genetic variant is linked to a higher risk and severity of Alopecia Areata in males.

The 3D skin model mimics pemphigus vulgaris and helps test treatments.

SOX10 in hair follicles is linked to inflammation in alopecia areata.

Etanercept may not prevent alopecia areata from coming back.

Targeting specific T cells may help treat alopecia areata.

ILC1-like cells can cause alopecia areata by disrupting hair follicle immunity, suggesting a new treatment approach.

Candida antigen is an effective and promising treatment for alopecia areata.

Clonally expanded CD8+ T cells cause alopecia areata.

Arab APS1 patients have unique and recurrent AIRE gene mutations.

New treatments for alopecia areata, like JAK inhibitors and immunomodulators, are promising.

New genetic discoveries in alopecia areata could lead to better treatments.

CD8A and FOXD2-AS1 may be key for diagnosing and treating alopecia areata.

CAR is a useful marker for assessing alopecia areata severity.

Targeting the AhR pathway may help treat alopecia areata.

The study found that alopecia areata is strongly linked to autoimmune diseases and may indicate a genetic predisposition to such conditions.

Certain immune cells contribute to skin autoimmune diseases, and some treatments can reverse hair loss in these conditions.

Cell-based therapy using specific immune cells may help treat alopecia areata by promoting hair regrowth.

Alopecia areata shows a unique type 1 interferon signature, suggesting potential treatment by targeting this pathway.

Too much IKZF1 and Ikaros protein may cause alopecia areata.